Cancer biomarkers refer to molecules that can indicate the presence or stage of cancer in the body. Biomarkers can be secreted by tumors or specific responses of the body to the presence of cancer. These biomarkers can be DNA, RNA, protein, peptide, and other small molecules, as well as the ratio of specific indexes. Biomarkers can be detected in tissues, cell lines, or non-invasively collected biological fluids (such as urine, blood or serum), which describes a normal or abnormal biological state and lays the foundation for early diagnosis of cancer. A variety of approaches can be adopted for cancer biomarker detection to promote the development of cancer diagnosis, treatment, prognosis and epidemiology.
Nowadays, cancer biomarker discovery has become a major focus of cancer research. In particular, non-invasively acquired biomarkers have great potential to improve cancer management in all aspects of screening, detection, diagnosis, staging, prognosis and assessment of treatment response. With the emergence of novel and improved multi-omics technologies, such as DNA and tissue microarrays, chromatography, mass spectrometry, and advanced bioinformatics tools, reliable and accurate prediction of biomarkers is tremendously facilitated.
Figure 1. Classification of biomarkers. (Mishra, 2010)
With cutting-edge and complete multi-omics platforms, Creative Proteomics provides a comprehensive one-stop biomarker discovery service for cancer research. We combine genomics, proteomics, metabolomics technologies together with bioinformatics platforms, which support various needs in biomarker detection, prediction, diagnosis, and prognosis. The validated biomarkers discovery service that we can offer covers DNA and RNA biomarkers, protein biomarkers, and other small molecules. Featured with high throughput and super-sensitivity, our protocols cover sample preparation, experiment design, sample preparation, biomarker detection, and data analysis for both targeted and untargeted biomarker processes. We are committed to promoting the understanding of cancer biomarkers and their applications in cancer.
A full set of multi-omics platforms for high-throughput biomarker assays
Compatible with a wide range of samples
Accurate detection and precise analysis of biomarkers
Targeted assays and non-targeted predictions
Extensive experience in bioinformatics analysis
Efficient workflow and reasonable pricing
Using the latest chromatography and mass spectrometry technology, Creative Proteomics provides comprehensive biomarker discovery solutions:
Cancer risk assessment
Diagnosis of cancer
Prognosis and treatment predictions
Pharmacodynamics and pharmacokinetics
Monitoring treatment response
Prediction of cancer recurrence
Drug target development
|Breast||ER/PR (estrogen receptor/progesteron receptor), HER-2/neu|
|Colorectal||EGFR, KRAS, UGT1A1|
|Leukemia/Lymphoma||CD20, CD30, FIP1L1-PDGFRalpha, PDGFR, Philadelphia Chromosome (BCR/ABL), PML/RAR-alpha, TPMT, UGT1A1|
|Lung||EML4/ALK, EGFR, KRAS|
|Pancreas||Elevated levels of leucine, isoleucine and valine|
|Non-specific biomarkers||NLR (neutrophil-to-lymphocyte ratio), Basic Fibroblast Growth Factor (bFGF), Insulin-like Growth Factor (IGF-R)|
Creative Proteomics is one of the most trustworthy companies that offer multi-omics technologies-based cancer research solutions. We are dedicated to providing the best strategies for your research. With state-of-the-art multi-omics and bioinformatics platforms, we provide fast and reliable cancer biomarker discovery services. For additional information and other services that we provide, please feel free to contact us.
Please contact us to find out how we can help you achieve the next research breakthrough.
1. Goossens N, Nakagawa S, Sun X, et al. Cancer biomarker discovery and validation. Translational cancer research. 2015, 4(3).
2. Sallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. Disease markers. 2015.
3. Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time?. Cancers. 2010, 2(1).
4. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. 2005.